Nanoform Finland (NANOFH) CMD 2025 Presentation summary

Strategic vision and business targets for 2026–2030

• Aims to break technological barriers in both small and large molecule drug development using CESS® for small molecules and BioLine for biologics, supporting the industry shift from IV to subcutaneous delivery.

• Targets over 300 non-GMP projects and more than 30 GMP projects by 2030, with three nanoformed medicines launched by that year.

• Sets ambitious financial goals: revenue exceeding €30 million, cumulative milestones over €30 million, and income growth above 50% CAGR from 2026–2030, with EBIT margin above 30%.

• Cost growth is projected to remain below 5% CAGR due to prior investments in manufacturing scale-up and digital infrastructure.

Industry context and technology differentiation

• Despite rising global pharma R&D spending, the number of new FDA drug approvals has remained flat, highlighting the need for innovative solutions.

• Nanoform’s technology addresses low transition rates from preclinical to GMP projects, aiming to reach industry standards by 2030.

• The CESS® process enables efficient, scalable nanoforming, with significant improvements in throughput and cost since 2021.

• BioLine technology produces highly stable, high-concentration biologic suspensions, validated by large pharma partners for injectable and pulmonary delivery.

Product pipeline and partnerships

• Pipeline includes nanoenzalutamide (prostate cancer), nanoapalutamide, nanoencorafenib (melanoma/colorectal cancer), and GLIORA (glioma), with launches targeted between 2028–2033.

• Strategic partnerships with Helm Pharmaceuticals, Brafmed, and Revio Therapeutics support product development, regulatory submissions, and commercialization.

• Nanoenzalutamide leverages a novel polymer-embedded nanoparticle platform to overcome existing patent and formulation hurdles, enabling smaller, patient-centric tablets.

• GLIORA, a long-acting intra-tumoral hydrogel for glioma, combines nanoformed APIs for synergistic local therapy, with a de-risked development plan and strong IP protection.